Developing switchable bispecific T-cell engagers to fight cancer Who we are We are an immuno-oncology company developing a next generation of bispecific T-cell engagers to treat patients with solid tumor cancers. Our mission is to safely harness the body’s natural immune system to defeat cancer and transform patients’ lives. LEARN MORE Our technology Our pioneering...
Location: United States, California, San Francisco
Member count: 11-50
Total raised: $42M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| 12.06.2021 | 5AM Ventur... | 5amventure... |
| 22.08.2022 | MBC BioLab... | mbcbiolabs... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 17.05.2021 | Series A | $42M | 5AM Ventur... | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 20.05.2021 | Soteria Bi... | SAN FRANCISCO, May 17, 2021: S... | - | - | m-ventures... |
| 17.05.2021 | Soteria Bi... | Soteria Biotherapeutics, Inc.,... | USA | - | finsmes.co... |
| 17.05.2021 | Soteria Bi... | SAN FRANCISCO, May 17, 2021 /P... | - | - | marketscre... |